News - China starts human trials of bird flu vaccine
BEIJING, Dec 21 (Reuters) - China has begun human trials of its homegrown bird flu vaccine with six volunteers receiving shots, the official Xinhua news agency said on Wednesday. A total of 120 people, aged from 18 to 60 and all from Beijing and in good health, had volunteered to take part in the trials, Xinhua said.
"After half an hour of clinical observation, the volunteers experienced no bad reaction of either the whole or part of the body," the agency said.
Though the trials will need nine months of tests, initial results are expected within the first three, it added.
Xinhua provided no further details.
China has had more than 30 outbreaks of the deadly H5N1 strain of bird flu that scientists fear could mutate from a disease which largely affects birds to one that can pass easily between people, leading to a human pandemic.
There have been 139 confirmed human cases of H5N1, all of them in Asia, including six in China. Two people have died from bird flu in China, out of 71 known fatalities in Asia.
The head of the company researching the vaccine, Sinovac Biotech, told Reuters last month that it was at least a year away from hitting the shelves.
Development of the vaccine -- called Panflu -- started last year after bird flu outbreaks in Thailand and Vietnam and animal trials have already been completed.
Experts say experimental vaccines for bird flu are unlikely to be a good match for an H5N1 strain that may eventually emerge in transmissible form among humans.
Using current technology it takes six months or more to make a new flu vaccine and there is no way to predict what a pandemic strain might look like.
Currently, Roche Pharmaceuticals'
Doctors believe it may help control a pandemic of H5N1, although evidence suggests it may be less effective than it is against seasonal influenza.
Reuters AlertNet - China starts human trials of bird flu vaccine